Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 175, Issue 5, 2007, Pages 450-457

  Boot, Johan Diderik ^a   De Haas, Sanne ^a   Tarasevych, Svetlana ^a   Roy, Christine ^c   Wang, Lin ^d   Amin, Dilip ^d   Cohen, Judith ^a   Sterk, Peter J ^b,c   Miller, Barry ^d   Paccaly, Anne ^d   Burggraaf, Jacobus ^a   Cohen, Adam F ^a   Diamant, Zuzana ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d SANOFI   (France)

Author keywords

Allergen bronchoprovocation test; Asthma; AVE5883; Neurokinin A bronchoprovocation test; Tachykinins

Indexed keywords

ALLERGEN; AVE 5883; METHACHOLINE; NEUROKININ A; NITRIC OXIDE; PLACEBO; TACHYKININ; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT; DIAGNOSTIC AGENT; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR;

ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; MALE; MULTIPLE CYCLE TREATMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; ADULT; BRONCHOSPASM; CYTOLOGY; DRUG ANTAGONISM; FOLLOW UP; FORCED EXPIRATORY FLOW; INHALATION TEST; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MIDDLE AGED; SPUTUM; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; ALLERGENS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY FLOW RATES; HUMANS; MALE; MIDDLE AGED; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-2; SPUTUM; TREATMENT OUTCOME;

EID: 33847659728     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200608-1186OC     Document Type: Article

References (46)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Bethesda MD: National Heart, Lung, and Blood Institute; World Health Organization; 2006.
2. Ward C, Reid DW, Orsida BE, Feltis B, Ryan VA, Johns DP, Walters EH. Inter-relationships between airway inflammation, reticular basement membrane thickening and bronchial hyper-reactivity to methacholine in asthma; a systematic bronchoalveolar lavage and airway biopsy analysis. Clin Exp Allergy 2005;35:1565-1571.
3. Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K. Safety of inhaled corticosteroids. Proc Am Thorac Soc 2004;1:171-175.
4. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanovic R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000;161:9-16.
5. Sont JK, Han J, van Krieken JM, Evertse CE, Hooijer R, Willems LN, Sterk PJ. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax 1996;51:496-502.
6. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJH, Pauwels RA, Pedersen SE, for the GOAL Investigators Group. Can guideline defined asthma control be achieved? The Gaining Optimal Asthma ControL Study. Am J Respir Crit Care Med 2004;170:836-844.
7. Heaney LG, Cross LJ, McGarvey LP, Buchanan KD, Ennis M, Shaw C. Neurokinin A is the predominant tachykinin in human bronchoalveolar lavage fluid in normal and asthmatic subjects. Thorax 1998;53:357-362.
8. Nieber K, Baumgarten CR, Rathsack R, Furkert J, Oehme P, Kunkel G. Substance P and beta-endorphin-like immunoreactivity in lavage fluids of subjects with and without allergic asthma. J Allergy Clin Immunol 1992;90:646-652.
9. Advenier C, Lagente V, Boichot E. The role of tachykinin receptor antagonists in the prevention of bronchial hyperresponsiveness, airway inflammation and cough. Eur Respir J 1997;10:1892-1906.
10. Van Rensen EL, Hiemstra PS, Rabe KF, Sterk PJ. Assessment of microvascular leakage via sputum induction: the role of substance P and neurokinin A in patients with asthma. Am J Respir Crit Care Med 2002;165:1275-1279.
11. Cheung D, van der Veen H, DenHartigh J, Dijkman JH, Sterk PJ. Effects of inhaled substance P on airway responsiveness to methacholine in asthmatic subjects in vivo. J Appl Physiol 1994;77:1325-1332.
12. Cheung D, Bel EH, Den Hartigh J, Dijkman JH, Sterk PJ. The effect of an inhaled neutral endopeptidase inhibitor, thiorphan, on airway responses to neurokinin A in normal humans in vivo. Am Rev Respir Dis 1992;145:1275-1280.
13. Cohen J, Burggraaf J, Schoemaker RC, Sterk PJ, Cohen AF, Diamant Z. Relationship between airway responsiveness to neurokinin A and methacholine in asthma. Pulm Pharmacol Ther 2005;18:171-176.
14. Adcock IM, Peters M, Gelder C, Shirasaki H, Brown CR, Barnes PJ. Increased tachykinin receptor gene expression in asthmatic lung and its modulation by steroids. J Mol Endocrinol 1993;11:1-7.
15. Bai TR, Zhou D, Weir T, Walker B, Hegele R, Hayashi S, McKay K, Bondy GP, Fong T. Substance P (NK1)- and neurokinin A (NK2)-receptor gene expression in inflammatory airway diseases. Am J Physiol 1995;269:L309-L317.
16. Tomaki M, Ichinose M, Miura M, Hirayama Y, Yamauchi H, Nakajima N, Shirato K. Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis. Am J Respir Crit Care Med 1995;151:613-617.
17. Ichinose M, Nakajima N, Takahashi T, Yamauchi H, Inoue H, Takishima T. Protection against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonist. Lancet 1992;340:1248-1251.
18. Joos GF, Vincken W, Louis R, Schelfhout VJ, Wang JH, Shaw MJ, Cioppa GD, Pauwels RA. Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir J 2004;23:76-81.
19. Van Schoor J, Joos GF,Chasson BL,Brouard RJ, Pauwels RA. The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics. Eur Respir J 1998;12:17-23.
20. Kraan J, Vink-Klooster H, Postma DS. The NK-2 receptor antagonist SR 48968C does not improve adenosine hyperresponsiveness and airway obstruction in allergic asthma. Clin Exp Allergy 2001;31:274-278.
21. Schelfhout V, Louis R, Lenz W, Heyrman R, Pauwels R, Joos G. The triple neurokinin-receptor antagonist CS-003 inhibits neurokinin Ainduced bronchoconstriction in patients with asthma. Pulm Pharmacol Ther 2006;19:413-418.
22. Boot J, Tarasevych S, Wang L, Sterk PJ, Miller B, Amin D, Cohen AF, Diamant Z. Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on allergen-induced airway responses and inflammation in asthma [abstract]. Proc Am Thorac Soc 2006;3:A80.
23. Diamant Z, De Haas S, Cohen J, Burggraaf J, Schoemaker RC, Sterk PJ, Wang L, Miller B, Krishna R, Cohen AF. Effect of inhaled AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma [abstract]. Eur Respir J 2004;24:1384.
24. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40.
25. Cheung D, Timmers MC, Zwinderman AH, Den Hartigh J, Dijkman JH, Sterk PJ. Neutral endopeptidase activity and airway hyperresponsiveness to neurokinin A in asthmatic subjects in vivo. Am Rev Respir Dis 1993;148:1467-1473.
26. Diamant Z, Kuperus J, Baan R, Nietzmann K, Millet S, Mendes P, Miller B, Amin D, Rohatagi S, Sterk PJ, et al. Effect of a very late antigen-4 receptor antagonist on allergen-induced airway responses and inflammation in asthma. Clin Exp Allergy 2005;35:1080-1087.
27. Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O'Byrne PM, Anderson SD, Juniper EF, Malo JL. Airway responsiveness: standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:53-83.
28. Efthimiadis A, Spanevello A, Hamid Q, Kelly MM, Linden M, Louis R, Pizzichini MM, Pizzichini E, Ronchi C, Van Overvel F, et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J 2002;20(Suppl):19S-23S.
29. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide: 2005. Am J Respir Crit Care Med 2005;171:912-930.
30. Aalbers R, Kauffman HF, Koeter GH, Postma DS, De Vries K, De Monchy JG. Dissimilarity in methacholine and adenosine 5 -monophosphate responsiveness 3 and 24 h after allergen challenge. Am Rev Respir Dis 1991;144:352-357.
31. Inman MD, Watson R, Cockcroft DW, Wong BJ, Hargreave FE, O'Byrne PM. Reproducibility of allergen-induced early and late asthmatic responses. J Allergy Clin Immunol 1995;95:1191-1195.
32. Joos GF, Van Schoor J, Kips JC, Pauwels RA. The effect of inhaled FK224, a tachykinin NK-1 and NK-2 receptor antagonist, on neurokinin A-induced bronchoconstriction in asthmatics. Am J Respir Crit Care Med 1996;153:1781-1784.
33. Schuiling M, Zuidhof AB, Zaagsma J, Meurs H. Role of tachykinin NK1 and NK2 receptors in allergen-induced early and late asthmatic reactions, airway hyperresponsiveness, and airway inflammation in conscious, unrestrained guinea pigs. Clin Exp Allergy 1999;29:48-52.
34. Schuiling M, Zuidhof AB, Zaagsma J, Meurs H. Involvement of tachykinin NK1 receptor in the development of allergen-induced airway hyper-reactivity and airway inflammation in conscious, unrestrained guinea pigs. Am J Respir Crit Care Med 1999;159:423-430.
35. Schuiling M, Zuidhof AB, Meurs H, Zaagsma J. Role of tachykinin NK2-receptor activation in the allergen-induced late asthmatic reaction, airway hyperreactivity and airway inflammatory cell influx in conscious, unrestrained guinea-pigs. Br J Pharmacol 1999;127:1030-1038.
36. Gauvreau GM, Doctor J, Watson RM, Jordana M, O'Byrne PM. Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med 1996;154:1267-1271.
37. Larsen BB, Nielsen LP, Engelstatter R, Steinijans V, Dahl R. Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy 2003;58:207-212.
38. Joos GF, Germonpre PR, Pauwels RA. Role of tachykinins in asthma. Allergy 2000;55:321-337.
39. Bowden J, Gibbins IL. Relative density of substance P-immunoreactive nerve fibres in the tracheal epithelium of a range of species [abstract]. FASEB J 1992;6:A1276.
40. Groneberg DA, Quarcoo D, Frossard N, Fischer A. Neurogenic mechanisms in bronchial inflammatory diseases. Allergy 2004;59:1139-1152.
41. Howarth PH, Djukanovic R, Wilson JW, Holgate ST, Springall DR, Polak JM. Mucosal nerves in endobronchial biopsies in asthma and non-asthma. Int Arch Allergy Appl Immunol 1991;94:330-333.
42. Fahy JV, Wong HH, Geppetti P, Reis JM, Harris SC, Maclean DB, Nadel JA, Boushey HA. Effect of an NK1 receptor antagonist (CP-99,994) on hypertonic saline-induced bronchoconstriction and cough in male asthmatic subjects. Am J Respir Crit Care Med 1995;152:879-884.
43. Barnes N, Piper PJ, Costello J. The effect of an oral leukotriene antagonist L-649,923 on histamine and leukotriene D4-induced bronchoconstriction in normal man. J Allergy Clin Immunol 1987;79:816-821.
44. Britton JR, Hanley SP, Tattersfield AE. The effect of an oral leukotriene D4 antagonist L-649,923 on the response to inhaled antigen in asthma. J Allergy Clin Immunol 1987;79:811-816.
45. Smith LJ, Glass M, Minkwitz MC. Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. Clin Pharmacol Ther 1993;54:430-436.
46. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337:690-694.